Takeda approves 100 JPY dividend and board elections

Takeda Pharmaceutical Company Limited reported the results of its 150th Annual General Meeting of Shareholders.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited reported the results of its 150th Annual General Meeting of Shareholders. Shareholders received reports on the business report and the consolidated and unconsolidated financial statements for the fiscal year from April 1, 2025 to March 31, 2026, along with the audit results.

They approved an appropriation of surplus that includes a year-end dividend of 100 JPY per share. Shareholders also elected eight directors who are not Audit and Supervisory Committee members, three directors who are Audit and Supervisory Committee members, and one substitute director for that committee.

The meeting further approved payment of bonuses within 260 million JPY in total to two directors who are not Audit and Supervisory Committee members, excluding directors residing outside Japan and external directors. Several directors, including all Audit and Supervisory Committee members, were designated as external directors under the Companies Act.

Key Figures

Year-end dividend: 100 JPY per share Director bonuses cap: 260 million JPY Directors (non-ASC): 8 directors +3 more

6 metrics

Year-end dividend 100 JPY per share Appropriation of surplus for 149th fiscal year

Director bonuses cap 260 million JPY Bonuses for two directors not on Audit and Supervisory Committee

Directors (non-ASC) 8 directors Elected who are not Audit and Supervisory Committee members

Directors (ASC members) 3 directors Elected as Audit and Supervisory Committee members

Substitute ASC director 1 director Paul Stoffels elected as substitute ASC member director

Fiscal year period April 1, 2025 to March 31, 2026 149th fiscal year covered by reported financial statements

Key Terms

External Directors, Audit and Supervisory Committee, Appropriation of Surplus, Business Report, +1 more

5 terms

External Directors regulatory

"Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka and Paul Stoffels are External Directors defined in Article 2, item 15 of the Companies Act."

Members of a company’s board of directors who are not current employees or executives of the company and who typically have no significant business ties to it. They act like outside referees, bringing independent judgment to oversight of management, strategy, and risks; their presence matters to investors because they can influence corporate decisions, monitor conflicts of interest, and help ensure transparent governance.

Audit and Supervisory Committee regulatory

"Election of Three (3) Directors who are Audit and Supervisory Committee Members"

An audit and supervisory committee is a board-level group that checks a company’s books, internal controls, and management decisions to help ensure financial reports are accurate and risks are controlled. Think of it as a combined watchdog and accounting review team that holds executives accountable and flags problems early, which matters to investors because it strengthens trust in financial statements and lowers the chance of surprise losses or fraud.

Appropriation of Surplus financial

"Proposal No.1: Appropriation of Surplus This item was approved as originally proposed."

Business Report financial

"The Business Report, Consolidated Financial Statements and Unconsolidated Financial Statements for the 149th fiscal year"

Consolidated Financial Statements financial

"The Business Report, Consolidated Financial Statements and Unconsolidated Financial Statements for the 149th fiscal year"

Consolidated financial statements combine the financial results of a parent company and all the companies it controls into one set of reports, like showing the whole family’s budget instead of each person’s separate accounts. For investors this matters because it gives a complete picture of assets, debts, revenue and cash flow across the entire group, helping assess true size, risk and profitability without missing or double-counting related activity.

FAQ

What dividend did Takeda (TAK) approve at the 150th Annual General Meeting?

Takeda approved a year-end dividend of 100 JPY per share as part of the appropriation of surplus. This payment relates to the 149th fiscal year from April 1, 2025 to March 31, 2026, and applies to shareholders of record for that period.

Which financial reports were presented at Takeda’s 150th Annual General Meeting?

Shareholders were presented with the Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements for the 149th fiscal year. They also received the results of audits of the consolidated financial statements by the Accounting Auditor and the Audit and Supervisory Committee.

How many directors did Takeda (TAK) elect who are not Audit and Supervisory Committee members?

Shareholders elected eight directors who are not Audit and Supervisory Committee members. Six directors were re-elected and two, Julie Kim and Paul Stoffels, were newly elected. Several of these directors are designated as external directors under the Companies Act.

What changes were made to Takeda’s Audit and Supervisory Committee membership?

Shareholders elected three directors who are Audit and Supervisory Committee members: one re-elected, Kimberly A. Reed, and two newly elected, Bruce Broussard and Koichiro Kimura. All are external directors as defined in Article 2, item 15 of the Companies Act.

What bonus payments to directors did Takeda (TAK) approve at the meeting?

Shareholders approved bonuses totaling up to 260 million JPY for two directors who are not Audit and Supervisory Committee members. These bonuses exclude directors residing outside Japan and external directors and apply to those in office at the end of the fiscal year.

Who was elected as substitute director for Takeda’s Audit and Supervisory Committee?

Shareholders elected Paul Stoffels as a substitute director who is an Audit and Supervisory Committee member. This role applies if the number of Audit and Supervisory Committee member directors falls below the statutory minimum, and the substitute is designated as an external director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:04 AM Learn about SEC filing dates

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-38757

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome

Chuo-ku, Tokyo 103-8668

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Information furnished on this form:

EXHIBIT

Exhibit Number
1						Notice of Resolutions at the 150th Annual General Meeting of Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

						TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: June 24, 2026						By:			/s/ Norimasa Takeda
									Norimasa Takeda Chief Accounting Officer and Corporate Controller

TRANSLATION: Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

June 24, 2026

To Our Shareholders

Julie Kim

President and Representative Director

Takeda Pharmaceutical Company Limited

1-1, Doshomachi 4-chome

Chuo-ku, Osaka 540-8645, Japan

Notice of Resolutions at the 150th Annual General Meeting of Shareholders

Dear Shareholders:

We hereby report as follows on the matters reported and on the resolutions made at the 150th Annual General Meeting of Shareholders of the Company held today.

Items reported:

1. The Business Report, Consolidated Financial Statements and Unconsolidated Financial Statements for the 149th fiscal year (from April 1, 2025 to March 31, 2026)

2. Results of audits of the Consolidated Financial Statements by the Accounting Auditor and Audit and Supervisory Committee for the 149th fiscal year

The contents of these documents were reported.

Items resolved:
Proposal No.1:						Appropriation of Surplus This item was approved as originally proposed. (The year-end dividend is 100 JPY per share.)
Proposal No.2:						Election of Eight (8) Directors who are not Audit and Supervisory Committee Members As proposed, Milano Furuta, Andrew Plump, Masami Iijima, Steven Gillis, John Maraganore and Miki Tsusaka were re-elected, Julie Kim and Paul Stoffels were newly elected, and all eight (8) Directors who are not Audit and Supervisory Committee Members assumed their respective offices. Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka and Paul Stoffels are External Directors defined in Article 2, item 15 of the Companies Act.

Proposal No.3:						Election of Three (3) Directors who are Audit and Supervisory Committee Members As proposed, Kimberly A. Reed was re-elected, Bruce Broussard and Koichiro Kimura were newly elected, and all three (3) Directors who are Audit and Supervisory Committee Members assumed their respective offices. All of them are External Directors defined in Article 2, item 15 of the Companies Act.
Proposal No.4:						Election of One (1) Substitute Director who is an Audit and Supervisory Committee Member In case the number of Directors who are Audit and Supervisory Committee (ASC) Members falls below the statutory minimum, the Company proposed the election of one (1) Substitute External Director who is an ASC Member. As proposed, Paul Stoffels was elected as the Substitute Director who is an ASC Member.
Proposal No.5:						Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members It was proposed and approved that the amount within 260 million JPY in total be paid to the two (2) Directors who are not Audit and Supervisory Committee Members (excluding Directors residing outside of Japan and External Directors) in office as of the end of this fiscal year.

End of Document